| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kevin J Li, Ronald J Gurrera, Lynn E Delis. Potentially fatal outcomes associated with clozapine. Schizophrenia research. vol 199. 2019-03-11. PMID:29503232. |
clozapine has been shown to be the most efficacious therapy for treatment resistant schizophrenia, estimated at one third of all schizophrenia cases. |
2019-03-11 |
2023-08-13 |
Not clear |
| Kevin J Li, Ronald J Gurrera, Lynn E Delis. Potentially fatal outcomes associated with clozapine. Schizophrenia research. vol 199. 2019-03-11. PMID:29503232. |
here we present a case of a 62-year-old man with chronic paranoid schizophrenia refractory to numerous antipsychotics who was started on clozapine therapy during an acute inpatient psychiatric admission. |
2019-03-11 |
2023-08-13 |
Not clear |
| Kristen Thien, Meghan Bowtell, Scott Eaton, Melissa Bardell-Williams, Linglee Downey, Aswin Ratheesh, Patrick McGorry, Brian O'Donoghu. Clozapine use in early psychosis. Schizophrenia research. vol 199. 2019-03-11. PMID:29525463. |
the superior efficacy of clozapine in treatment resistant schizophrenia has been clearly demonstrated, yet there are often delays in the commencement of clozapine. |
2019-03-11 |
2023-08-13 |
Not clear |
| Cristian Mena, Alfonso Gonzalez-Valderrama, Barbara Iruretagoyena, Juan Undurraga, Nicolas A Crossle. Early treatment resistance in a Latin-American cohort of patients with schizophrenia. Schizophrenia research. vol 199. 2019-03-11. PMID:29526456. |
we here present an analysis of clozapine prescription patterns, used as a real-world proxy marker for treatment-resistance, in a cohort of 1195 patients with schizophrenia from a latin-american cohort, to explore the timing of emergence of treatment resistance and possible subgroup differences. |
2019-03-11 |
2023-08-13 |
Not clear |
| Beatriz Rebollo, Maria Perez-Zabalza, Marcel Ruiz-Mejias, Lorena Perez-Mendez, Maria V Sanchez-Vive. Beta and Gamma Oscillations in Prefrontal Cortex During NMDA Hypofunction: An In Vitro Model of Schizophrenia Features. Neuroscience. vol 383. 2019-03-07. PMID:29723576. |
the observed action of clozapine decreasing hypersynchronization in the local circuit may be one of the mechanisms of action of clozapine in preventing schizophrenia symptoms derived from nmda hypofunction. |
2019-03-07 |
2023-08-13 |
Not clear |
| Vincenzo Monda, Monica Salerno, Francesco Sessa, Renato Bernardini, Anna Valenzano, Gabriella Marsala, Christian Zammit, Roberto Avola, Marco Carotenuto, Giovanni Messina, Antonietta Messin. Functional Changes of Orexinergic Reaction to Psychoactive Substances. Molecular neurobiology. vol 55. issue 8. 2019-02-26. PMID:29307079. |
antipsychotic drugs are used often to treat several psychiatric disorders, including schizophrenia and bipolar disorder however, antipsychotic drugs prescription, particularly the second-generation ones (sgas), such as clozapine and olanzapine, is related to a considerable weight gain which usually leads to obesity. |
2019-02-26 |
2023-08-13 |
human |
| Tarun Bastiampillai, Olivia Tonnu, Prashant Tibrewal, Rohan Dhillo. Why not clozapine for the patient with schizophrenia at risk of suicide? Asian journal of psychiatry. vol 26. 2019-02-25. PMID:28483094. |
why not clozapine for the patient with schizophrenia at risk of suicide? |
2019-02-25 |
2023-08-13 |
Not clear |
| A Alachkar, L Wang, R Yoshimura, A R Hamzeh, Z Wang, N Sanathara, S M Lee, X Xu, G W Abbott, O Civell. Prenatal one-carbon metabolism dysregulation programs schizophrenia-like deficits. Molecular psychiatry. vol 23. issue 2. 2019-02-15. PMID:28809400. |
finally, therapeutic actions of typical (haloperidol) and atypical (clozapine) antipsychotics in met mice mimicked effects in human schizophrenia patients. |
2019-02-15 |
2023-08-13 |
mouse |
| Sara Medved, Zvonimir Ostojić, Hrvoje Jurin, Vesna Medve. Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review. Croatian medical journal. vol 59. issue 6. 2019-02-11. PMID:30610773. |
we describe a case of a 40-year-old male patient, with a history of schizophrenia and heavy caffeine and nicotine use, treated for acute psychotic episode with haloperidol and clozapine. |
2019-02-11 |
2023-08-13 |
Not clear |
| Brent Luu, George W Rodway, Elizabeth Ric. Should we be targeting sleep architecture to more effectively treat schizophrenia? JAAPA : official journal of the American Academy of Physician Assistants. vol 31. issue 12. 2019-01-30. PMID:30489392. |
this article discusses the use of polysomnography to characterize the sleeping patterns of patients diagnosed with schizophrenia and the positive influence of clozapine on sleep in patients with schizophrenia. |
2019-01-30 |
2023-08-13 |
Not clear |
| Hong Shen, Danyang Wu, Shanshan Wang, Mengjie Zhao, Wenbo Sun, Xiaozhou Zhu, Ning Zhang, Hui Yao, Qing Cui, Hong Xia. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Basic & clinical pharmacology & toxicology. vol 123. issue 6. 2019-01-29. PMID:29938908. |
data were collected for 452 patients with eligible schizophrenia: 163 treated with clozapine, 186 treated with olanzapine, 47 treated with quetiapine and 56 receiving no medication. |
2019-01-29 |
2023-08-13 |
Not clear |
| Hong Shen, Danyang Wu, Shanshan Wang, Mengjie Zhao, Wenbo Sun, Xiaozhou Zhu, Ning Zhang, Hui Yao, Qing Cui, Hong Xia. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Basic & clinical pharmacology & toxicology. vol 123. issue 6. 2019-01-29. PMID:29938908. |
this study is the first to confirm that aap administration, especially clozapine and olanzapine, could increase lp-pla2 levels and cvd risk, independent of drug-induced weight gain in schizophrenia. |
2019-01-29 |
2023-08-13 |
Not clear |
| Rusmir Softic, Alija Sutovic, Esmina Avdibegovic, Enes Osmanović, Elvir Bećirović, Mitra Mirković Hajduko. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Psychiatria Danubina. vol 27. issue 4. 2019-01-28. PMID:26609650. |
metabolic syndrome in schizophrenia - who is more to blame: fga polypharmacy or clozapine monotherapy? |
2019-01-28 |
2023-08-13 |
Not clear |
| Rusmir Softic, Alija Sutovic, Esmina Avdibegovic, Enes Osmanović, Elvir Bećirović, Mitra Mirković Hajduko. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Psychiatria Danubina. vol 27. issue 4. 2019-01-28. PMID:26609650. |
to establish the prevalence of metabolic syndrome and its parameters in group of patients with schizophrenia in polypharmacy - receiving first generation antipsychotics versus clozapine alone treated group. |
2019-01-28 |
2023-08-13 |
Not clear |
| Edith J Chau, Md Shaki Mostaid, Vanessa Cropley, Patrick McGorry, Christos Pantelis, Chad A Bousman, Ian P Everal. Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 85. 2019-01-17. PMID:29577944. |
measurement of peripheral mrna levels showed no difference between treatment-resistant schizophrenia and healthy controls (p = 0.234) but clozapine plasma levels (p = 0.036) and duration of illness (p = 0.028) were positively correlated with mrna levels. |
2019-01-17 |
2023-08-13 |
Not clear |
| Belén Arranz, Marina Garriga, Clemente García-Rizo, Luis Sa. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 2. 2019-01-14. PMID:29273271. |
clozapine use in patients with schizophrenia and a comorbid substance use disorder: a systematic review. |
2019-01-14 |
2023-08-13 |
Not clear |
| Selene Veerman, Peter Schulte, Lieuwe de Haa. Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. Psychopharmacology. vol 234. issue 23-24. 2019-01-10. PMID:29038824. |
memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. |
2019-01-10 |
2023-08-13 |
Not clear |
| Robert J Feeley, Bachaar Arnaout, Gihyun Yoo. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal of clinical psychopharmacology. vol 37. issue 6. 2019-01-07. PMID:29028689. |
effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder. |
2019-01-07 |
2023-08-13 |
Not clear |
| Heeyoung Lee, Britney B Scolieri, Prabir K Mullic. Learned lessons from patients who take clozapine: A case study. Perspectives in psychiatric care. vol 54. issue 4. 2018-12-11. PMID:28926097. |
the purpose of this report is to provide clinical strategies to manage patients with schizophrenia taking clozapine. |
2018-12-11 |
2023-08-13 |
Not clear |
| David D Kim, Donna J Lang, Ric M Procyshyn, Melissa L Woodward, Kai Kaufman, Randall F White, William G Honer, Darren E R Warburto. Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. Psychiatry research. vol 262. 2018-12-11. PMID:29407565. |
reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |